Key clinical point: The reductions in primary endpoints among patients with heart failure with reduced ejection fraction (HFrEF) on empagliflozin matched the benefit seen before from dapagliflozin in DAPA-HF.

Major finding: Patients with HFrEF treated with the SGLT2 inhibitor empagliflozin (Jardiance) had a statistically significant 25% relative cut in their incidence of cardiovascular death or first heart failure hospitalization, compared with placebo controls when added on top of standard HFrEF treatment.

Study details: EMPEROR-Reduced randomized 3,730 HFrEF patients, with or without diabetes, to receive empagliflozin or placebo for an average of 16 months.

Disclosures: EMPEROR-Reduced was funded by Boehringer Ingelheim and Eli Lilly. Dr. Packer has received personal fees from Boehringer Ingelheim and Eli Lilly and from several other companies.